REPL•benzinga•
Piper Sandler Maintains Overweight on Replimune Group, Raises Price Target to $22
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga